// App-Quantinova.ai

1169 : Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial

Researchers

Presenter

  • Amy C.M. Musiek

Principal Investigators

  • Sean Whittaker

  • Steven M. Horwitz

  • Martine Bagot

  • Auris Huen

  • David C. Fisher

  • Paul Haun

  • Maarten H. Vermeer

  • Takahiro Ito

  • Karen Dwyer

  • Fiona Herr

  • Youn H. Kim

Medical Centers

  • Washington University School of Medicine, St. Louis, MO

  • Kings College London, London, United Kingdom

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Hopital Saint-Louis, AP-HP, Universite Paris , Paris, France

  • 1.MD Anderson Cancer Center, Houston, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

  • Leiden University Medical Centre, Leiden, Netherlands

  • Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ

  • Kyowa Kirin, Inc., Bedminster, NJ

Locations

  • United States

  • United Kingdom

  • France

  • Netherlands

Companies

  • Kyowa Kirin Pharmace

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Mogamulizumab

  • Vorinostat

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT01728805

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved